Published in Lab Anim Sci on April 01, 1999
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest (2008) 2.11
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest (2002) 1.74
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother (2008) 0.99
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res (2010) 0.96
Toll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function. J Biol Chem (2013) 0.87
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunol Immunother (2011) 0.82
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunol Immunother (2016) 0.80
Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. J Biol Chem (2013) 0.77
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS One (2016) 0.77
A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. Mol Ther Methods Clin Dev (2015) 0.75
Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control. Oncotarget (2017) 0.75
Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iran J Basic Med Sci (2015) 0.75
A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell (1983) 18.86
Detection of specific hybridoma clones by replica immunoadsorption of their secreted antibodies. Proc Natl Acad Sci U S A (1979) 13.60
Natural history of acute coronary heart attacks. A community study. Br Heart J (1972) 8.55
Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci U S A (1983) 5.18
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A (1984) 3.32
High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science (1989) 3.00
Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol (1989) 2.67
Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature (1986) 2.49
The x gene is essential for HTLV replication. Science (1985) 2.44
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol (1989) 2.42
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J (1988) 2.40
Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol (1997) 2.13
Natural history of unstable angina. Lancet (1972) 2.03
A quantitative difference in the immune response between male and female mice. Proc Soc Exp Biol Med (1968) 1.90
The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med (1991) 1.88
Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry (1995) 1.87
Polypeptide products of nonsense mutations. I. Termination fragments from nonsense mutations in the Z gene of the lac operon of Escherichia coli. J Mol Biol (1970) 1.84
Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods (1992) 1.74
Heavy chain-producing variants of a mouse myeloma cell line. J Immunol (1975) 1.73
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 1.73
Prognosis of new and worsening angina pectoris. Br Med J (1976) 1.59
Murine heavy chain disease. Eur J Immunol (1978) 1.50
The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med (1984) 1.46
A second isolate of HTLV-II associated with atypical hairy-cell leukemia. N Engl J Med (1986) 1.44
A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors. Anal Biochem (1991) 1.40
Estimation of antibodies specific for dextran. J Immunol (1978) 1.38
Detection and cloning of new HTLV-related endogenous sequences in man. Nucleic Acids Res (1989) 1.36
Production and properties of chimeric antibody molecules. Methods Enzymol (1989) 1.35
Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. J Immunol (1986) 1.34
Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood (1994) 1.33
Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol (1997) 1.32
Characterization of the J chain from polymeric immunoglobulins (IgA-IgM-immunological specificity-primary structure). Proc Natl Acad Sci U S A (1972) 1.31
Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res (2000) 1.31
Patterns of repair of dystrophic mouse muscle: studies on isolated fibers. Dev Dyn (1999) 1.29
Regulation of immunoglobulin expression in mouse myeloma cells. Cold Spring Harb Symp Quant Biol (1977) 1.28
Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans. J Immunol (1987) 1.27
Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci U S A (1990) 1.26
Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. Blood Rev (1997) 1.22
Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. Oncogene (1989) 1.22
Aging normal and dystrophic mouse muscle: analysis of myogenicity in cultures of living single fibers. Muscle Nerve (1998) 1.21
Myeloma mutant with a novel 3' flanking region: loss of normal sequence and insertion of repetitive elements leads to decreased transcription but normal processing of the alpha heavy-chain gene products. Mol Cell Biol (1986) 1.21
Transfectomas provide novel chimeric antibodies. Science (1985) 1.20
Policy for early discharge after acute myocardial infarction. Br Med J (1980) 1.19
Bone-marrow suppression associated with cimetidine. Ann Intern Med (1979) 1.17
Sequentially derived mutants of the constant region of the heavy chain of murine immunoglobulins. J Immunol (1979) 1.16
Sequences near the 3' secretion-specific polyadenylation site influence levels of secretion-specific and membrane-specific IgG2b mRNA in myeloma cells. Mol Cell Biol (1986) 1.16
Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med (1994) 1.16
Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol (1998) 1.15
Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol (1999) 1.15
Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci U S A (1987) 1.15
Transfer and expression of immunoglobulin genes. Annu Rev Immunol (1984) 1.15
Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J Biol Chem (1999) 1.14
Two alpha heavy chain disease proteins with different genomic deletions demonstrate that nonexpressed alpha heavy chain genes contain methylated bases. Proc Natl Acad Sci U S A (1981) 1.13
Immunochemical characterization of binding sites of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran. Mol Immunol (1982) 1.12
Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet (1991) 1.12
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med (1991) 1.12
Loss of a consensus splice signal in a mutant immunoglobulin gene eliminates the CH1 domain exon from the mRNA. Mol Cell Biol (1984) 1.09
Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J (1991) 1.09
Ultraviolet-Stimulated KHCO(3) Efflux from Rose Cells: Regulation of Cytoplasmic pH. Plant Physiol (1983) 1.09
A histochemical method for the simultaneous demonstration of capillaries and fiber type in skeletal muscle. Stain Technol (1987) 1.07
The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med (2000) 1.06
Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood (1993) 1.06
Association constants of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran determined by affinity electrophoresis. Mol Immunol (1982) 1.05
Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region. Proc Natl Acad Sci U S A (1987) 1.05
The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer (1994) 1.05
Regulation of HTLV-II gene expression by Rex involves positive and negative cis-acting elements in the 5'long terminal repeat. Virology (1991) 1.04
Polypyrimidine tract-binding protein and heterogeneous nuclear ribonucleoprotein A1 bind to human T-cell leukemia virus type 2 RNA regulatory elements. J Virol (1995) 1.03
Human T-cell leukemia virus type II Rex binding and activity require an intact splice donor site and a specific RNA secondary structure. J Virol (1991) 1.03
Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen. J Exp Med (1988) 1.03
In vitro mutagenesis of the human T-cell leukemia virus types I and II tax genes. J Virol (1989) 1.03
Specific binding of polypyrimidine tract binding protein and hnRNP A1 to HIV-1 CRS elements. Virus Genes (1996) 1.02
Developmental regulation of membrane and secretory Ig gamma 2b mRNA. J Immunol (1989) 1.01
The identification of mouse myeloma cells which have undergone mutations in immunoglobulin production. Soc Gen Physiol Ser (1974) 1.01
Studies on mouse hybridomas secreting IgM or IgA antibodies to alpha(1 to 6)-linked dextran. Mol Immunol (1981) 1.01
Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res (1999) 0.99
Mutational events in mouse myeloma cells. Crit Rev Immunol (1981) 0.99
Sequences of variable regions of hybridoma antibodies to alpha (1----6) dextran in BALB/c and C57BL/6 mice. J Immunol (1985) 0.98
Determination of heroin and its metabolites by high-performance liquid chromatography. J Chromatogr (1982) 0.98
Expression of a VHC kappa chimaeric protein in mouse myeloma cells. Nature (1984) 0.98
Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci U S A (1995) 0.98
Mutation of the methylated tRNA(Lys)(3) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1. J Virol (2001) 0.97
Somatically generated mouse myeloma variants synthesizing IgA half-molecules. J Exp Med (1981) 0.97
Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc Natl Acad Sci U S A (1992) 0.97
Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest (1999) 0.96
Mapping studies reveal unique epitopes on IgG recognized by rheumatoid arthritis-derived monoclonal rheumatoid factors. J Immunol (1993) 0.96
Production of secretory immunoglobulin A by a single mammalian cell. Proc Natl Acad Sci U S A (1997) 0.96
Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. J Immunol Methods (1993) 0.95
Appearance of an early "primed state" in mice following the concomitant injections of antigen and specific antiserum. J Immunol (1972) 0.95
Inhibition of HIV-1 replication using a mutated tRNALys-3 primer. J Biol Chem (1997) 0.95
Ectopic skeletal muscles derived from myoblasts implanted under the skin. J Cell Sci (1998) 0.94
Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther (1997) 0.94
A common sequence motif near nonhomologous recombination breakpoints involving Ig sequences. J Immunol (1993) 0.93
Divergence of human alpha-chain constant region gene sequences. A novel recombinant alpha 2 gene. J Immunol (1994) 0.93